NCT02849041 (DETeCTOR) is a NA clinical trial of medical imaging in Tobacco, sponsored by Fondation Hôpital Saint-Joseph.

Who is sponsoring NCT02849041?

NCT02849041 is sponsored by Fondation Hôpital Saint-Joseph.

What drugs are being tested in NCT02849041?

Interventions in NCT02849041: medical imaging, Identification of Circulating Tumor Cells, Psychological Questionnaires.

What condition does NCT02849041 study?

NCT02849041 studies Tobacco, Cancer, Screening, Psychology, Lung.

Is NCT02849041 still recruiting?

NCT02849041 is currently status unknown. Last updated 7 March 2023.

Last reviewed 2023-03-07 · How we verify

NCT02849041: DETeCTOR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Screening of Tobacco-induced Cancers by Low-dose CT-scanner and Identification of Circulating Tumor Cells

Status unknown NA Last updated 7 March 2023

What this trial tests

NA trial testing medical imaging in Tobacco in 176 participants. Status unknown.

Timeline

23 January 2017

Primary endpoint
20 July 2020

23 December 2023

Quick facts

Lead sponsor	Fondation Hôpital Saint-Joseph
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	176
Start date	23 January 2017
Primary completion	20 July 2020
Estimated completion	23 December 2023
Sites	1 location across France

Drugs / interventions tested

medical imaging
Identification of Circulating Tumor Cells — full drug profile →
Psychological Questionnaires

Conditions studied

Tobacco — all drugs for Tobacco →
Cancer — all drugs for Cancer →
Screening — all drugs for Screening →
Psychology — all drugs for Psychology →

Sponsor

Fondation Hôpital Saint-Joseph — full company profile →

Who can join

Adults 55 to 80, any sex, with Tobacco or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tobacco smoke is the most common source of exposure to carcinogens in humans. Indeed, the smoke contains about 1010 particles per ml and 4800 chemical compounds, at least 66 are carcinogenic. Tobacco smoke is the leading preventable cause of cancer in humans since it is responsible for lung cancer, upper aerodigestive tract (mouth, pharynx, larynx, esophagus), nasal cavity and sinuses, stomach, pancreas, liver, bladder, kidney, uterine cervix, and some myeloid leukemias. This study aims to evaluate the combined effect of the scanner and the search for circulating tumor cells (CTC) on screening for tobacco-related cancers, accompanying smokers to cessation and addressing the psychological impact this approach.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Redefining cancer care: harnessing circulating tumor cells' potential for improved diagnosis and prognosis.
Janjua D, Chaudhary A, Joshi U, Tripathi T, et al · · 2025 · cited 4× · PMID 40676582 · DOI 10.1186/s12935-025-03883-y
Peripheral arterial disease and systematic detection of circulating tumor cells: rationale and design of the DETECTOR prospective cohort study.
Yannoutsos A, Fontaine M, Galloula A, Damotte D, et al · · 2019 · cited 4× · PMID 31519196 · DOI 10.1186/s12872-019-1193-1

Verify or expand the search:

Other recruiting trials for Tobacco

Currently open trials in the same condition.

NCT06832085 — Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation · Phase 4 · recruiting
NCT05038852 — Acceptability of Mobile Applications (Apps) to Enhance Smoking Cessation in a Clinical Tobacco Treatment Program - A Pil · NA · active not recruiting
NCT02797275 — Secondhand Smoke Respiratory Health Study · Phase 4 · active not recruiting

Other Fondation Hôpital Saint-Joseph trials

Trials by the same sponsor.

NCT07512960 — Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia After Distal Revascularization · Phase 3 · not yet recruiting
NCT07512908 — Study of Factors Influencing the Dynamics of Colonisation and Decolonisation of the Digestive Tract by Clostridioides Di · NA · not yet recruiting
NCT07512830 — Evaluation of the Benefits of Hypnosis During Transoesophageal Echocardiography · NA · recruiting
NCT07348081 — Real World Evidence to Assess the Value of a Digital Care Coordination and Monitoring Program for Supporting Caregivers · NA · recruiting
NCT07086612 — Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) and Transverse Orthodontic Deficiency in Children · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02849041 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondation Hôpital Saint-Joseph
Last refreshed: 7 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02849041.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing